This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
PET/CT imaging with a new gallium-68-based prostate cancer radiotracer shows promise for detecting recurrent metastatic disease, according to a study published February 20 in the Journal of NuclearMedicine. The finding is from a phase I/II clinical trial in the U.S. HU = Houndsfield unit; SUVbw = body-weight SUV.
Nuclearmedicine is a form of specialty medicine that uses radioactive tracers to evaluate bodily functions and to diagnose and treat a wide range of health conditions. Nuclearscans produce images of the body’s anatomy that cannot be obtained as clearly or fully with other imaging techniques.
An article in the Journal of NuclearMedicine reports findings of a multi-center retrospective study that compares bonescan with PSMA PET for initial staging of prostate cancer.
Technetium-99m (Tc-99m) methyl diphosphonate (MDP) bonescans are a potentially viable noninvasive option for diagnosing calciphylaxis, according to a team at the University of Massachusetts in Worcester, MA. The team assessed the potential diagnostic utility of bonescans in calciphylaxis based on a review of the literature.
Several presenters at the Society for NuclearMedicine and Molecular Imaging's (SNMMI) 2024 meeting in Toronto shared new findings in women's studies. Gayton oversees clinical operations at Precirix and serves as the company's chief development officer. Women's theranostics appears to already be on the horizon.
In this phase II clinical trial, the researchers sought to evaluate the approach further. Radiologists and nuclearmedicine physicians analyzed the images, with their reads ultimately compared to laboratory results from biopsies.
We organize all of the trending information in your field so you don't have to. Join 5,000 users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content